Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Traws Pharma Inc TRAW

Healthcare Biotechnology
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir... see more

Current News (NDAQ:TRAW)

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

GlobeNewswire February 19, 2026

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

GlobeNewswire January 26, 2026

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

GlobeNewswire January 13, 2026

Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID(TM), Shows Activity in PAXLOVID-Ineligible COVID-19 Patients

GlobeNewswire December 17, 2025

Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

GlobeNewswire November 13, 2025

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

PR Newswire October 30, 2025

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

PR Newswire October 22, 2025

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

GlobeNewswire October 14, 2025

Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

GlobeNewswire October 6, 2025
View More News ››

Opinion & Analysis (NDAQ:TRAW)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:TRAW)

Sell buddy sell.

Otherwise LOSE - O for you fellas out there today
coolfooldumbguy - December 17, 2025

Buy buddy buy because it's taking off this morning.

Otherwise you guys out there will be missing out on this stock today
coolfooldumbguy - June 3, 2025

Buy buddy buy.

It looks like this stock will be climbing up from here .
coolfooldumbguy - February 13, 2025

Using dollar cost averaging for this stock.

It is a good company and it is a good way to buy shares of this company.So that you can get a good price for this one.
coolfooldumbguy - January 16, 2025

This stock is a good buy at these low prices and

It is starting to climb up from the bottom of the year.
coolfooldumbguy - January 13, 2025

RE:RE:RE:RE:RE:What’s going on with ONTX stock?

Selfish and self serving management. No conscience.
Mukulu20 - May 16, 2022
View more Bullboard ››

Nuclear Vision Ltd.

Nuclear Vision Ltd.

Nuclear Vision Limited operates as a uranium exploration company. Its material property is the Regnault Project that consists ...
View More »

Podcasts